- Home
- ALNY vs DB Comparison
ALNY vs DB Comparison
Compare ALNY & DB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- DB
- Stock Information
- Founded
- ALNY 2002
- DB 1870
- Country
- ALNY United States
- DB Germany
- Employees
- ALNY N/A
- DB N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- DB Major Banks
- Sector
- ALNY Health Care
- DB Finance
- Exchange
- ALNY Nasdaq
- DB Nasdaq
- Market Cap
- ALNY 34.7B
- DB 33.6B
- IPO Year
- ALNY 2004
- DB N/A
- Fundamental
- Price
- ALNY $244.89
- DB $16.21
- Analyst Decision
- ALNY Buy
- DB Buy
- Analyst Count
- ALNY 23
- DB 2
- Target Price
- ALNY $298.59
- DB N/A
- AVG Volume (30 Days)
- ALNY 928.6K
- DB 1.8M
- Earning Date
- ALNY 10-31-2024
- DB 10-23-2024
- Dividend Yield
- ALNY N/A
- DB 3.02%
- EPS Growth
- ALNY N/A
- DB N/A
- EPS
- ALNY N/A
- DB 2.11
- Revenue
- ALNY $2,094,795,000.00
- DB $30,817,532,890.00
- Revenue This Year
- ALNY $25.14
- DB N/A
- Revenue Next Year
- ALNY $17.13
- DB $3.26
- P/E Ratio
- ALNY N/A
- DB $7.25
- Revenue Growth
- ALNY 21.54
- DB 1.70
- 52 Week Low
- ALNY $141.98
- DB $12.05
- 52 Week High
- ALNY $304.39
- DB $17.95
- Technical
- Relative Strength Index (RSI)
- ALNY 37.82
- DB 38.88
- Support Level
- ALNY $229.86
- DB $16.58
- Resistance Level
- ALNY $250.71
- DB $16.89
- Average True Range (ATR)
- ALNY 8.80
- DB 0.23
- MACD
- ALNY -2.59
- DB -0.06
- Stochastic Oscillator
- ALNY 26.50
- DB 12.67
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About DB Deutsche Bank AG
Deutsche Bank is a universal bank operating on a global scale. The bank offers corporate, retail, investment banking, private banking, and asset management to its clients.